EIF2S1 (eukaryotic translation initiation factor 2 subunit α) is a heterotrimeric protein and a regulatory subunit of eIF2 . eIF2 has three general subunits- α, βand γ . eIF2α is located on human chromosome 14q23 .
Immunogen
The antiserum was produced against synthesized peptide derived from human eIF2 alpha around the phosphorylation site of Ser51.
Immunogen Range: 21-70
Application
Anti-phospho-eIF2 α(pSer51) antibody has been used in western blotting and immunohistochemistry.
Biochem/physiol Actions
EIF2S1 (eukaryotic translation initiation factor 2 subunit α) acts as a modulator in apoptosis signaling pathway . During endoplasmic reticulum stress, eIF2α plays a major role in signaling pathways in the development of tumor .
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Next-generation sequencing has contributed to our understanding of the genetics of Alzheimer's disease (AD) and has explained a substantial part of the missing heritability of familial AD. We sequenced 19 exomes from 8 Dutch families with a high AD burden
Translational regulator eIF2? in tumor
Zheng Q, et al.
Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine, 35(7), 6255-6264 (2014)
Human molecular genetics, 30(8), 687-705 (2021-03-23)
Mutations in CHCHD10, coding for a mitochondrial intermembrane space protein, are a rare cause of autosomal dominant amyotrophic lateral sclerosis. Mutation-specific toxic gain of function or haploinsufficiency models have been proposed to explain pathogenicity. To decipher the metabolic dysfunction associated
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
